US-based health care company Baxter International and mRNA-based therapeutics and vaccines maker Moderna have reached an agreement for the latter’s Covid-19 Vaccine.
Under the partnership, Baxter BioPharma Solutions will provide fill/finish sterile manufacturing and packaging services for nearly 60-90 million doses of the Moderna Covid-19 Vaccine in 2021.
Baxter said that its BioPharma Solutions business is a contract manufacturing organisation that specialises in parenteral (injectable) pharmaceuticals, including vaccines.
Moderna chief technical operations and quality officer Juan Andres said: “We welcome the opportunity to work with Baxter BioPharma Solutions on fill/finish manufacturing for the Moderna Covid-19 Vaccine in the US.
“This additional production will help us continue to scale up our manufacturing capacity in the United States.”
Baxter would manufacture the Moderna Covid-19 vaccine at its fill/finish sterile manufacturing facilities located in Bloomington, Indiana.
The BioPharma Solutions company has been operating in Bloomington for nearly 20 years, employing more than 700 individuals on its 600,000ft2 campus.
The Bloomington site has expertise in parenteral delivery systems and clinical and commercial vaccine manufacturing, including preventive and seasonal vaccines.
Also, the site offers a variety of production and commercialisation services, including clinical development, formulation, packaging and commercial launch capabilities, said the company.
Baxter BioPharma Solutions vice president Marie Keeley said: “We have seen a remarkable demonstration of scientific and health care expertise in the effort to develop vaccines for Covid-19.
“Baxter is honoured to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine.”
